Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (91-100 of 238) with videos related to

Pageof 24
Sort By:
Clinical Drug Investigation|October 19, 2023
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy SubjectsMarion Anliker-Ort, Jasper Dingemanse, Luboš Janů, et al.
Clinical Pharmacokinetics|February 27, 2003
Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatinJasper Dingemanse, Dieter Schaarschmidt, Paul L M van Giersbergen
European Journal of Clinical Pharmacology|December 15, 2019
Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjectsMarie-Laure Boof, Atef Halabi, Mike Ufer, et al.
British Journal of Clinical Pharmacology|November 23, 2019
Modelling pharmacokinetics and pharmacodynamics of the selective S1P<sub>1</sub> receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patientsDominik Lott, Pierre-Eric Juif, Jasper Dingemanse, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 6, 2021
Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y<sub>12</sub> receptor between selatogrel and oral P2Y<sub>12</sub> antagonistsAndrea Henrich, Christian Hove Claussen, Jasper Dingemanse, et al.
Pharmacology|July 3, 2013
Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sexShirin Bruderer, Joanne Marjason, Patricia N Sidharta, et al.
Pulmonary Pharmacology & Therapeutics|May 13, 2014
Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjectsNicolas Lindegger, Patricia N Sidharta, Kathrin Reseski, et al.
Pharmacology|August 26, 2011
Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjectsMatthias Hoch, Petra Hoever, Federica Alessi, et al.
Pharmacology|November 2, 2018
Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male SubjectsPatricia N Sidharta, Paul L M van Giersbergen, Jasper Dingemanse
British Journal of Clinical Pharmacology|March 18, 2006
Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjectsJasper Dingemanse, Kulasiri A Gunawardena, Paul L M van Giersbergen
Pageof 24

Showing results (91-100 of 238) with videos related to

Sort By:
Pageof 24
Clinical Drug Investigation|October 19, 2023
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy SubjectsMarion Anliker-Ort, Jasper Dingemanse, Luboš Janů, et al.
Clinical Pharmacokinetics|February 27, 2003
Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatinJasper Dingemanse, Dieter Schaarschmidt, Paul L M van Giersbergen
European Journal of Clinical Pharmacology|December 15, 2019
Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjectsMarie-Laure Boof, Atef Halabi, Mike Ufer, et al.
British Journal of Clinical Pharmacology|November 23, 2019
Modelling pharmacokinetics and pharmacodynamics of the selective S1P<sub>1</sub> receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patientsDominik Lott, Pierre-Eric Juif, Jasper Dingemanse, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 6, 2021
Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y<sub>12</sub> receptor between selatogrel and oral P2Y<sub>12</sub> antagonistsAndrea Henrich, Christian Hove Claussen, Jasper Dingemanse, et al.
Pharmacology|July 3, 2013
Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sexShirin Bruderer, Joanne Marjason, Patricia N Sidharta, et al.
Pulmonary Pharmacology & Therapeutics|May 13, 2014
Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjectsNicolas Lindegger, Patricia N Sidharta, Kathrin Reseski, et al.
Pharmacology|August 26, 2011
Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjectsMatthias Hoch, Petra Hoever, Federica Alessi, et al.
Pharmacology|November 2, 2018
Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male SubjectsPatricia N Sidharta, Paul L M van Giersbergen, Jasper Dingemanse
British Journal of Clinical Pharmacology|March 18, 2006
Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjectsJasper Dingemanse, Kulasiri A Gunawardena, Paul L M van Giersbergen
Pageof 24